FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2781483265> ?p ?o ?g. }

• W2781483265 abstract "Glycosuria produced by sodium–glucose co-transporter-2 (SGLT-2) inhibitors is associated with weight loss. SGLT-2 inhibitors reportedly might reduce the occurrence of cardiovascular events. Epicardial adipose tissue (EAT) is a pathogenic fat depot that may be associated with coronary atherosclerosis. The present study evaluated the relationship between an SGLT-2 inhibitor (dapagliflozin) and EAT volume. In 40 diabetes mellitus patients with coronary artery disease (10 women and 30 men; mean age of all 40 patients was 67.2 ± 5.4 years), EAT volume was compared prospectively between the dapagliflozin treatment group (DG; n = 20) and conventional treatment group (CTG; n = 20) during a 6-month period. EAT was defined as any pixel that had computed tomography attenuation of − 150 to − 30 Hounsfield units within the pericardial sac. Metabolic parameters, including HbA1c, tumor necrotic factor-α (TNF-α), and plasminogen activator inhibitor-1 (PAI-1) levels, were measured at both baseline and 6-months thereafter. There were no significant differences at baseline of EAT volume and HbA1c, PAI-1, and TNF-α levels between the two treatment groups. After a 6-month follow-up, the change in HbA1c levels in the DG decreased significantly from 7.2 to 6.8%, while body weight decreased significantly in the DG compared with the CTG (− 2.9 ± 3.4 vs. 0.2 ± 2.4 kg, p = 0.01). At the 6-month follow-up, serum PAI-1 levels tended to decline in the DG. In addition, the change in the TNF-α level in the DG was significantly greater than that in the CTG (− 0.5 ± 0.7 vs. 0.03 ± 0.3 pg/ml, p = 0.03). Furthermore, EAT volume significantly decreased in the DG at the 6-month follow-up compared with the CTG (− 16.4 ± 8.3 vs. 4.7 ± 8.8 cm3, p = 0.01). Not only the changes in the EAT volume and body weight, but also those in the EAT volume and TNF-α level, showed significantly positive correlation. Treatment with dapagliflozin might improve systemic metabolic parameters and decrease the EAT volume in diabetes mellitus patients, possibly contributing to risk reduction in cardiovascular events." @default.
• W2781483265 created "2018-01-12" @default.
• W2781483265 creator A5004710280 @default.
• W2781483265 creator A5009021038 @default.
• W2781483265 creator A5021340166 @default.
• W2781483265 creator A5034342190 @default.
• W2781483265 creator A5042769627 @default.
• W2781483265 creator A5046153736 @default.
• W2781483265 creator A5049548909 @default.
• W2781483265 creator A5055227838 @default.
• W2781483265 creator A5085481597 @default.
• W2781483265 creator A5087201504 @default.
• W2781483265 creator A5089185800 @default.
• W2781483265 date "2018-01-04" @default.
• W2781483265 modified "2023-10-14" @default.
• W2781483265 title "The effect of dapagliflozin treatment on epicardial adipose tissue volume" @default.
• W2781483265 cites W135321714 @default.
• W2781483265 cites W1518443297 @default.
• W2781483265 cites W1580333814 @default.
• W2781483265 cites W1965569235 @default.
• W2781483265 cites W1990417844 @default.
• W2781483265 cites W1991334358 @default.
• W2781483265 cites W1995324236 @default.
• W2781483265 cites W1996344640 @default.
• W2781483265 cites W1999444321 @default.
• W2781483265 cites W2021517048 @default.
• W2781483265 cites W2023205017 @default.
• W2781483265 cites W2027589607 @default.
• W2781483265 cites W2038623844 @default.
• W2781483265 cites W2040445576 @default.
• W2781483265 cites W2062571251 @default.
• W2781483265 cites W2063655399 @default.
• W2781483265 cites W2069650182 @default.
• W2781483265 cites W2098076446 @default.
• W2781483265 cites W2100271953 @default.
• W2781483265 cites W2101333957 @default.
• W2781483265 cites W2102844001 @default.
• W2781483265 cites W2109815357 @default.
• W2781483265 cites W2111116814 @default.
• W2781483265 cites W2113658685 @default.
• W2781483265 cites W2130570549 @default.
• W2781483265 cites W2139959600 @default.
• W2781483265 cites W2142593697 @default.
• W2781483265 cites W2145697808 @default.
• W2781483265 cites W2145729769 @default.
• W2781483265 cites W2146264128 @default.
• W2781483265 cites W2150140397 @default.
• W2781483265 cites W2167245776 @default.
• W2781483265 cites W2224883440 @default.
• W2781483265 cites W2284028653 @default.
• W2781483265 cites W2302367542 @default.
• W2781483265 cites W2323202746 @default.
• W2781483265 cites W2337473245 @default.
• W2781483265 cites W2460082513 @default.
• W2781483265 cites W2576291926 @default.
• W2781483265 cites W2591986567 @default.
• W2781483265 cites W2604392184 @default.
• W2781483265 cites W2619744261 @default.
• W2781483265 cites W2624808517 @default.
• W2781483265 cites W2756345767 @default.
• W2781483265 cites W4249727000 @default.
• W2781483265 cites W948379226 @default.
• W2781483265 doi "https://doi.org/10.1186/s12933-017-0658-8" @default.
• W2781483265 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5753537" @default.
• W2781483265 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29301516" @default.
• W2781483265 hasPublicationYear "2018" @default.
• W2781483265 type Work @default.
• W2781483265 sameAs 2781483265 @default.
• W2781483265 citedByCount "211" @default.
• W2781483265 countsByYear W27814832652018 @default.
• W2781483265 countsByYear W27814832652019 @default.
• W2781483265 countsByYear W27814832652020 @default.
• W2781483265 countsByYear W27814832652021 @default.
• W2781483265 countsByYear W27814832652022 @default.
• W2781483265 countsByYear W27814832652023 @default.
• W2781483265 crossrefType "journal-article" @default.
• W2781483265 hasAuthorship W2781483265A5004710280 @default.
• W2781483265 hasAuthorship W2781483265A5009021038 @default.
• W2781483265 hasAuthorship W2781483265A5021340166 @default.
• W2781483265 hasAuthorship W2781483265A5034342190 @default.
• W2781483265 hasAuthorship W2781483265A5042769627 @default.
• W2781483265 hasAuthorship W2781483265A5046153736 @default.
• W2781483265 hasAuthorship W2781483265A5049548909 @default.
• W2781483265 hasAuthorship W2781483265A5055227838 @default.
• W2781483265 hasAuthorship W2781483265A5085481597 @default.
• W2781483265 hasAuthorship W2781483265A5087201504 @default.
• W2781483265 hasAuthorship W2781483265A5089185800 @default.
• W2781483265 hasBestOaLocation W27814832651 @default.
• W2781483265 hasConcept C126322002 @default.
• W2781483265 hasConcept C134018914 @default.
• W2781483265 hasConcept C141071460 @default.
• W2781483265 hasConcept C164705383 @default.
• W2781483265 hasConcept C171089720 @default.
• W2781483265 hasConcept C187954543 @default.
• W2781483265 hasConcept C2777180221 @default.
• W2781483265 hasConcept C2777422806 @default.
• W2781483265 hasConcept C2778213512 @default.
• W2781483265 hasConcept C2781214132 @default.
• W2781483265 hasConcept C500558357 @default.
• W2781483265 hasConcept C511355011 @default.

• next